Streetbeat News

Revenues

EWG

Germany's unemployment change for January showed a decrease of 2,000, beating the estimate of an 11,000 increase and improving from the prior 5,000 increase. This indicates a stronger German labor market than expected.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 9:04 am

UMC

United Microelectronics Corp (UMC) reported that revenue from 22/28nm technology nodes grew to 36% of wafer revenue, while the 40nm node contributed 14% of sales.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 8:47 am

UMC

United Microelectronics Corp (UMC) forecasts a 2%-3% increase in Q1 wafer shipments year-over-year, with a 5% decline in average selling price (ASP) and a gross profit margin of around 30%. The company anticipates a low-60% capacity utilization and plans a CAPEX of $3.3 billion for 2024.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 8:45 am

NVS

Novartis projects a 5% compound annual growth rate (CAGR) in net sales from 2023 to 2028 at constant currency. The company also anticipates its core operating income margin to expand to over 40% by 2027.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 8:20 am

SDZNY

Sandoz, a global leader in generic and biosimilar medicines, has launched Tyruko (natalizumab), the first and only biosimilar for treating relapsing-remitting multiple sclerosis (RRMS) in Germany as of February 1. Tyruko, developed by Polpharma Biologics, is indicated as a single disease-modifying therapy in adults with highly active RRMS, mirroring the indication of the reference medicine Tysabri. Rebecca Guntern, President Europe of Sandoz, emphasized the importance of early treatment with DMTs for MS patients and the role of Tyruko in enhancing access to effective therapies in Europe.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 7:54 am

EWQ

France's Harmonised Index of Consumer Prices (HICP) showed a preliminary monthly decrease of 0.2%, aligning with estimates and contrasting with the 0.1% increase in the prior period.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 7:52 am

EWG

Germany's Retail Sales for December 2022 decreased by 1.6%, which was below the estimated 0.7% increase and also lower than the revised prior figure of -0.8%.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 7:41 am

EWU

The U.K. Nationwide Housing Price Index for January showed a year-on-year decrease of 0.2%, which is an improvement compared to the estimated decline of 0.9% and the previous month's decrease of 1.8%.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 7:40 am

MESO

Mesoblast Limited reported advancements in Phase 3 trials and financial results, including $1.5M in royalty revenue from TEMCELL HS Inj.5 sales in Japan. The company completed a capital raise of A$60.3 million and reported a cash balance of A$113.4 million. Cost containment strategies led to a reduction in net operating cash spend, with further reductions planned for FY2024. Mesoblast received FDA's Rare Pediatric Disease Designation for Revascor and plans to discuss regulatory approval pathways.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 7:10 am

EWA

Australia's Consumer Price Index (CPI) for Q4 came in at 0.6%, lower than the estimated 0.8% and the previous 1.2%. This indicates a slower pace of inflation than expected.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 5:14 am